An Open-Label, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics fo the PARP Inhibitor AZD2461 in Patients With Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2012
At a glance
- Drugs AZD 2461 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 05 Jun 2012 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 05 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.